compounded glp-1 fda What Changed? The FDA's Clarification on Drugs FDA Moves to Restrict Mass-Marketed

Based on the above pharmacological characteristics of categories of GLP-1RAs agents, despite slight adverse gastrointestinal side effects, it is clear that GLP-1RAs agents have efficacy in cardiovascular protection without untoward hypoglycemia

doi: 10.3389/fphar.2025.1567863 Received 28 January 2025 Accepted 21 April 2025 Published 01 May 2025 Volume 16 - 2025 Edited by Miguel Oliveira, University of Aveiro, Portugal Reviewed by Yuling Han, Chinese Academy of Sciences (CAS), China Gary Ten Eyck, New York University, United States Satish Polshettiwar, MIT World Peace University, India Updates Copyright 2025 Feng, Qu and Hao

Published 2024 Nov 18

Twenty participants with a BMI of 30 or greater, half on a maintenance dose of GLP-1s and half taking no medication, were recruited from Roanoke and surrounding areas

For that reason, claims that a patch can match the effects of prescription GLP-1 therapy should be viewed carefully unless supported by strong clinical data

www.isbtweb.org